Endomorphin-1 alters interleukin-8 secretion in Caco-2 cells via a receptor mediated process

Neudeck, Brien L.; Loeb, Jennifer M.

doi:10.1016/s0165-2478(02)00198-0

Cited by 23 publications

(11 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Moreover, chronic administration of morphine inhibited tumorigenesis and metastasis [35] and reduced liver metastasis in animals [36]. Yet, other authors showed that morphine at a concentration of 100 nM stimulated the release of urokinase type plasminogen activator, a factor known to promote metastasis [21] and that the activation of MOR was associated with a significant increase in the release of interleukin-8 [37]. We found no association between total perioperative 96 h opioid use with DFS or OS.…”

Section: Discussioncontrasting

confidence: 61%

Mu Opioid Receptor 1 (MOR-1) Expression in Colorectal Cancer and Oncological Long-Term Outcomes: A Five-Year Retrospective Longitudinal Cohort Study

Díaz‐Cambronero

Mazzinari

Giner

et al. 2020

Cancers

View full text Add to dashboard Cite

Preclinical evidence has shown increased expression of mu opioid receptor 1 (MOR-1) in colorectal cancer although its association with disease-free and overall survival (DFS and OS) has not been investigated. We hypothesized that MOR-1 was overexpressed in tumor samples compared to normal tissue and this was associated with decreased DFS and OS. We carried out a retrospective study assessing the association of MOR-1 tumor expression with long-term outcomes by immunohistochemistry in normal and tumor samples from 174 colorectal cancer patients. The primary endpoint was five years of DFS. Secondary endpoints were five years of OS, the difference in MOR-1 expression between normal and tumor tissue and the occurrence of postoperative complications. Multivariable Cox regression showed no significant association between MOR-1 expression and DFS (HR 0.791, 95% CI 0.603–1.039, p = 0.092). MOR-1 expression was higher in tumor tissue compared to non-tumor tissue. No associations were found between MOR-1 expression and OS or postoperative complications. These findings suggest that although MOR-1 is over-expressed in colorectal cancer samples there is no association to increased risk of recurrence or mortality. Future studies are warranted to elucidate the role of cancer stage, genetic polymorphism, and quantitative assessment of MOR-1 over-expression on long-term outcomes in colorectal cancer.

show abstract

Section: Discussioncontrasting

confidence: 61%

Mu Opioid Receptor 1 (MOR-1) Expression in Colorectal Cancer and Oncological Long-Term Outcomes: A Five-Year Retrospective Longitudinal Cohort Study

Díaz‐Cambronero

Mazzinari

Giner

et al. 2020

Cancers

View full text Add to dashboard Cite

show abstract

“…A similar effect was observed with ␤-endorphin, which is an agonist at and ␦ receptors (Sundar et al, 1995), whereas the KOR agonist dynorphin inhibited cytokine induced up-regulation of HIV expression (Chao et al, 1995). Endomorphin-1 was further reported to alter IL-10 and IL-12 release from T-cells (Azuma and Ohura, 2002) and IL-8 production in colon cancer cells (Neudeck and Loeb, 2002). Most studies addressing the effects of ␤-endorphin on immunocytes found immunosuppressive effects in the form of inhibition of proliferation or reduction of pro-inflammatory cytokine release (Garcia et al, 1992;Panerai et al, 1995;Bhardwaj et al, 1996;Ientile et al, 1997;Hosoi et al, 1999;Takeba et al, 2001).…”

Section: A Inhibition Of Inflammation With Endogenous Opioidsmentioning

confidence: 54%

Opioids As Modulators of Cell Death and Survival—Unraveling Mechanisms and Revealing New Indications

2004

View full text Add to dashboard Cite

“…Neudeck and Loeb reported the expression of MORs in the intestinal epithelial cell line, Caco-2, at the mRNA level as well as immunocytochemically using a goat polyclonal antibody to the amino terminus of the human MOR (Santa Cruz Biotechnology; presumably the same antibody as that used in the current study). Interestingly, the immunoreactivity was confined to the surfaces of the cell [14]. In a ligand binding assay in the HT-29 cell line, Hytrek et al demonstrated that while binding of [Met 5 ]enkephalin (a specific agonist at the fOR) was confined to the nuclear component of the fractionized cells, binding of the MOR ligand, [D-Ala 2 ,N-Me-Phe 4 , Gly 5 -ol] enkephalin (DAMGO), could only be found in the plasma membrane fraction [15].…”

Section: Current Results Of Morphine Effects On Colon Cancer Cellsmentioning

confidence: 99%

Functional Expression of μ-Opioid Receptors in the Human Colon Cancer Cell Line, HT-29, and their Localization in Human Colon

et al. 2007

View full text Add to dashboard Cite

We have investigated the functional expression of mu-opioid receptors (MORs) in the human colon cancer cell line, HT-29. As revealed by immunocytochemistry, immunoreactivity was present in both the cytoplasm and nuclei of the cells. Challenge with morphine for 24 h (1 nM to 1 microM) barely affected cell proliferation, while the secretion of urokinase type plasminogen activator (a protease involved in invasion/metastasis) was markedly augmented by a concentration of 0.1 microM. Human colon cancer tissue from 14 consecutively operated patients was investigated by immunohistochemistry. MORs were found in the nuclei of colonocytes and immune cells of the lamina propria in tumor-free tissue. In tumor tissue, immunoreactivity was found in the membrane and often in the nuclei of tumor cells. The current findings suggest that morphine administration could affect tumor progression by interfering with, for example, invasive properties. Our demonstration of a nuclear expression of the MORs appears to be a novel finding.

show abstract

Endomorphin-1 alters interleukin-8 secretion in Caco-2 cells via a receptor mediated process

Cited by 23 publications

References 18 publications

Mu Opioid Receptor 1 (MOR-1) Expression in Colorectal Cancer and Oncological Long-Term Outcomes: A Five-Year Retrospective Longitudinal Cohort Study

Mu Opioid Receptor 1 (MOR-1) Expression in Colorectal Cancer and Oncological Long-Term Outcomes: A Five-Year Retrospective Longitudinal Cohort Study

Opioids As Modulators of Cell Death and Survival—Unraveling Mechanisms and Revealing New Indications

Functional Expression of μ-Opioid Receptors in the Human Colon Cancer Cell Line, HT-29, and their Localization in Human Colon

Contact Info

Product

Resources

About